CATX Perspective Tx: רווח למניה אחת ב-12 החודשים האחרונים

Perspective Therapeutics (CATX) develops radiopharmaceuticals, where hospital supply stability and high margins are secured through a network of protected express-delivery hubs. This EPS (TTM) chart shows the current figure at 14.30. The business relies on the urgent air transport of short-lived isotopes. However, R&D expenses are currently depleting capital, while the risk of rare material supply disruptions and expansion by pharma behemoths are creating significant pressure.

The investment attractiveness of Perspective Therapeutics (CATX) is based on the independence of its product cycle from macroeconomic fluctuations. This indicator captures the dynamics of net earnings per share over a rolling year, reflecting the actual efficiency of innovation capitalization. By analyzing the historical EPS YoY growth over the last 12 months, an investor assesses the resilience of cash flows to external shocks. The positive trajectory of this metric confirms the fundamental strength of this defensive asset.